DeepMed Research

Takeda Pharmaceutical Company Ltd

🇯🇵Japan

Country: 🇯🇵Japan

Ownership: -

Established: 1925-01-01

Employees: -

Market Cap: $47.5B

Website: http://www.takeda.co.jp/

Clinical Trials

A Study of Darvadstrocel in Adults With Crohn's Disease and Complex Perianal Fistula

Phase 4

Terminated

Conditions: Crohn's Disease
Complex Perianal Fistula

Interventions: Biological: Darvadstrocel

First Posted Date: 2019-10-08

Last Posted Date: 2025-03-17

Lead Sponsor: Takeda

Target Recruit Count: 53

Registration Number: NCT04118088

Locations: 🇩🇪
Charite - Campus Benjamin Franklin, Berlin, Germany
🇩🇪
Klinikum Dresden, University Hospital Dresden, Dresden, Sachsen, Germany
🇩🇪
Stadtisches Klinikum Luneburg, Luneburg, Schleswig-Holstein, Germany

and more 27 locations

Health-Related Quality of Life in Crohn's Disease Participants With Complex Perianal Fistula Before and After Treatment

Terminated

Conditions: Crohn Disease
Inflammatory Bowel Disease
Gastrointestinal Diseases
Intestinal Diseases

First Posted Date: 2019-09-25

Last Posted Date: 2021-07-27

Lead Sponsor: Takeda

Target Recruit Count: 19

Registration Number: NCT04102163

Locations: 🇪🇸
Hospital Universitario de Salamanca, Salamanca, Castilla Y Leon, Spain
🇪🇸
Hospital Gregorio Maranon, Madrid, Comunidad De Madrid, Spain
🇪🇸
Hospital Universitario Rio Hortega, Valladolid, Castilla Y Leon, Spain

and more 17 locations

A Study of TAK-994 in Adults With Type 1 and Type 2 Narcolepsy

Phase 2

Terminated

Conditions: Narcolepsy Type 1 (NT1)
Narcolepsy Type 2 (NT2)

Interventions: Drug: Placebo
Drug: TAK-994

First Posted Date: 2019-09-20

Last Posted Date: 2024-10-29

Lead Sponsor: Takeda

Target Recruit Count: 97

Registration Number: NCT04096560

Locations: 🇺🇸
Santa Monica Clinical Trials, Los Angeles, California, United States
🇺🇸
Florida Pulmonary Research Institute, LLC, Winter Park, Florida, United States
🇺🇸
SDS Clinical Trials, Inc., Santa Ana, California, United States

and more 75 locations

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of TAK-988 in Healthy Participants

Phase 1

Withdrawn

Conditions: Healthy Volunteers

Interventions: Drug: TAK-988
Drug: TAK-988 Placebo

First Posted Date: 2019-09-09

Last Posted Date: 2021-11-26

Lead Sponsor: Takeda

Registration Number: NCT04082481

Locations: 🇺🇸
PRA Health Sciences - Salt Lake City, Millcreek, Utah, United States
🇺🇸
Parexel Internalional - Glendale, Glendale, California, United States

Long-term Follow-up Study With Darvadstrocel in the Treatment of Complex Perianal Fistula

Phase 3

Completed

Conditions: Complex Perianal Fistula
Crohn's Disease

Interventions: Other: Placebo
Biological: Darvadstrocel

First Posted Date: 2019-09-03

Last Posted Date: 2025-04-23

Lead Sponsor: Takeda

Target Recruit Count: 150

Registration Number: NCT04075825

Locations: 🇪🇸
Hospital Clinico San Carlos, Madrid, Spain
🇺🇸
Virginia Mason Medical Center - Gastroenterology, Seattle, Washington, United States
🇺🇸
University of Miami Hospital, Miami, Florida, United States

and more 55 locations

A Study of TAK-981 Given With Rituximab in Adults With Relapsed or Refractory CD20-Positive Non-Hodgkin Lymphoma

Phase 1

Terminated

Conditions: Lymphoma, Non-Hodgkin

Interventions: Drug: TAK-981
Drug: Rituximab

First Posted Date: 2019-08-30

Last Posted Date: 2024-06-14

Lead Sponsor: Takeda

Target Recruit Count: 38

Registration Number: NCT04074330

Locations: 🇺🇸
East Carolina University, Greenville, North Carolina, United States
🇺🇸
Ohio State University Wexner Medical Center, Columbus, Ohio, United States
🇺🇸
University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States

and more 56 locations

Specified Drug-Use Survey on Vedolizumab for IV Infusion 300 mg [Crohn's Disease]

Active, not recruiting

Conditions: Crohn's Disease

Interventions: Drug: Vedolizumab (Genetical Recombination)

First Posted Date: 2019-06-28

Last Posted Date: 2024-07-10

Lead Sponsor: Takeda

Target Recruit Count: 335

Registration Number: NCT04002180

Locations: 🇯🇵
Takeda Selected Site, Tokyo, Japan

Long-Term Safety and Antibody Persistence of TDV and the Impact of a Booster Dose

Phase 3

Completed

Conditions: Dengue Fever

Interventions: Biological: Takeda's Dengue Tetravalent Vaccine (Live, Attenuated) (TDV)
Biological: Placebo

First Posted Date: 2019-06-27

Last Posted Date: 2024-05-31

Lead Sponsor: Takeda

Target Recruit Count: 365

Registration Number: NCT03999996

Locations: 🇺🇸
AES - DRS - Synexus Clinical Research US, Inc. Minneapolis, Richfield, Minnesota, United States
🇺🇸
Advanced Clinical Research/Velocity Clinical Research, West Jordan, Utah, United States
🇲🇽
Instituto Nacional de Pediatria, Ciudad De Mexico, Mexico

and more 7 locations

A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)

Phase 1

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: TAK-079
Drug: Lenalidomide
Drug: Dexamethasone
Drug: Bortezomib
Drug: Pomalidomide

First Posted Date: 2019-06-12

Last Posted Date: 2025-02-05

Lead Sponsor: Takeda

Target Recruit Count: 50

Registration Number: NCT03984097

Locations: 🇺🇸
American Oncology Partners of Maryland, PA, Bethesda, Maryland, United States
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Pacific Cancer Care, Monterey, California, United States

and more 6 locations

Perianal Fistula (PAF) Validation and Burden of Illness Study

Completed

Conditions: Crohns Disease
Perianal Fistula
Inflammatory Bowel Disease

Interventions: Other: No intervention

First Posted Date: 2019-06-11

Last Posted Date: 2021-04-21

Lead Sponsor: Takeda

Target Recruit Count: 3032

Registration Number: NCT03981939

Locations: 🇨🇦
Takeda Canada, Oakville, Ontario, Canada

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy